Screener
CONMED CNMD D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by CONMED in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: CONMED’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000816956-26-000102
Amortization expense related to intangible assets which are subject to amortization totaled $8.7 million for both the three months ended June 30, 2026 and 2025, and $17.5 million and $17.3 million for the six months ended June 30, 2026 and 2025, respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and
Item 1. Financial Statements (unaudited)
FAQ
- What is CONMED's D&A?
- CONMED (CNMD) reported D&A of $7.24M in Q2 2026.
- How has CONMED's D&A changed year-over-year?
- CONMED's D&A decreased by 16.8% year-over-year, from $8.7M to $7.24M.
- What is the long-term trend for CONMED's D&A?
- Over 4 years (2021 to 2025), CONMED's D&A has grown at a 1.5% compound annual growth rate (CAGR), from $33.2M to $35.2M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about CONMED's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude